Brennan’s Abrupt Departure Has Some Viewing AstraZeneca As A Buyout Target

A rough first quarter and news of the CEO’s decision to step down in slightly over a month leads to speculation that AstraZeneca could be an attractive M&A target for another pharma that might shut down the company’s struggling R&D effort and cash in on the existing portfolio.